Ketamine: Dependence, Bladder Damage, and Recovery Support

Ketamine is a dissociative anesthetic. It is an operating-room drug, the parent molecule of a nasal spray for hard-to-treat depression, and the powder people snort at parties, order from telehealth clinics, and, increasingly, use every day at home. The DEA controls it in Schedule III (DEA Diversion Control, 2025). In England, the number of people entering treatment for a ketamine problem rose 12-fold in ten years, from 426 in 2014/2015 to 5,365 in 2024/2025 (ACMD, 2026). Ketamine is hard to stop for a reason that surprises people: the withdrawal is mild next to alcohol or opioids, but the craving is not, and tolerance climbs fast enough that a weekend habit becomes a gram a day before anyone names it. This page covers dependence, the bladder and liver damage that set ketamine apart, treatment, and how weekly support at home fits.

What ketamine is and how it works

Ketamine hydrochloride was approved in 1970 as Ketalar, an injectable anesthetic indicated "as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation" (Ketalar prescribing information, 2020). Its active form, esketamine, is sold as Spravato, a nasal spray for treatment-resistant depression (Spravato prescribing information, 2025). Compounded lozenges and street powder are off-label or illegal.

The DEA lists the street names as "Special K, K, Kit Kat, Cat Valium, Super Acid, Special La Coke, Purple, Jet, and Vitamin K," and notes that "Ketamine powder is usually snorted, mixed in drinks, or smoked" while liquid ketamine "is injected, applied on a smokable material, or consumed in drinks" (DEA, 2025). At low doses it lifts mood and softens the edges; at higher doses it "distorts perceptions of sight and sound and makes the user feel disconnected and not in control" (DEA fact sheet).

The label describes ketamine as "a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor" (section 12.1). It does not act on opioid receptors or GABA, which is why withdrawal looks so different from opioids or alcohol. It is short-acting: the DEA puts the effects at "approximately 30 to 60 minutes" (DEA, 2025), and the label describes an initial phase "lasting about 45 minutes with a half-life of 10 to 15 minutes" (section 12.3). A short high invites redosing all evening.

Use is rising. The National Survey on Drug Use and Health found that "approximately 762,000 (0.3%) used ketamine in 2022 and 943,000 (0.3%) used ketamine in 2023" among Americans 12 and older (DEA, 2025). Part of that is the therapy boom. In October 2023 the FDA warned about compounded ketamine taken at home for psychiatric conditions, stating plainly that "Ketamine is not FDA approved for the treatment of any psychiatric disorder" (FDA, 2023). Many of our ketamine members started with a real prescription and a real depression.

Dependence, misuse, and addiction are not the same thing

Start with the label. The Ketalar prescribing information states that "Physical dependence has been reported with prolonged use of ketamine," defines it as "a state that develops as a result of physiological adaptation in response to repeated drug use," and adds that "Tolerance has been reported with prolonged use of ketamine" (section 9.3). Tolerance and dependence are what ketamine does to a nervous system that sees it often. They are pharmacology, not a verdict on your character.

Misuse is using it outside how it was prescribed: doubling the troche, buying powder to bridge the gap between refills. The Spravato label defines abuse as "intentional, non-therapeutic use of a drug, even once, for its psychological or physiological effects" (section 9.2). Addiction, a ketamine use disorder in clinical language, is continuing despite harm: the bladder pain, the memory gaps, the money, and the fact that you have tried to stop and could not. The UK's advisory council describes the pattern as "dose escalation because of increasing tolerance to the drug, together with development of dependency and withdrawal symptoms" (ACMD, 2026). Someone can be dependent on a prescribed dose and never misuse it. Someone can be addicted on what looks like a small amount.

Signs ketamine has become a problem

Here is what families and members describe to us most often. A gram that used to last a month is gone in a weekend. Use has moved from parties to weeknights to mornings, alone. Bathroom trips every half hour, pain when peeing, blood in the urine, or accidents at night, which the person may be too embarrassed to mention until a coach asks directly. Stomach cramps with no diagnosis. Memory that is noticeably worse: repeated questions, lost threads, missed appointments. Lozenges from a telehealth clinic that run out early. A partner who says "he's just not here anymore." The bladder and stomach symptoms matter most, because they mean organ damage is underway and because they usually improve if use stops soon (Andrade, J Clin Psychiatry, 2025). Any one of these is worth a conversation. Several together are worth a call.

Is stopping ketamine dangerous?

Medically, stopping ketamine is rarely dangerous in itself. There is no seizure risk of the kind alcohol and benzodiazepine withdrawal carry, and no equivalent of the lost-tolerance overdose that kills people returning to opioids. Both FDA labels describe the same picture: "Reported symptoms of withdrawal associated with daily intake of large doses of ketamine include craving, fatigue, poor appetite, and anxiety" (Ketalar, section 9.3; Spravato, section 9.3). The ACMD says "Discontinuation of heavy ketamine use can result in withdrawal symptoms that may last several days," and is candid that "The evidence available on managing withdrawal and dependency remains limited and of low quality" (ACMD, 2026). We could not find a primary source that defines a validated ketamine withdrawal syndrome with a scale and a timeline, so treat what follows as pattern, not protocol.

The danger is in continuing. Ketamine's harms accumulate with dose and years: a bladder that scars, bile ducts that dilate, memory that slips, injuries while dissociated. The people who need a clinician when stopping are those whose bladder or liver is already injured, whose depression was being self-treated with the drug, or who drink or use benzodiazepines alongside it. A stop that feels physically easy can still be psychologically brutal, and severe low mood afterward deserves medical eyes.

Ketamine withdrawal timeline

Everyone differs, and the pattern depends on dose, days per week, years of use, and what else is in the picture. This is the shape members describe.

First 24 hours

Craving arrives first and hardest, often within hours of the last dose. Restlessness, irritability, poor sleep, and sweating are common.

Days 2 to 4

The peak for most people: fatigue, no appetite, anxiety, and low mood that can feel like the old depression arriving all at once. Cravings are strongest at the times of day use had become routine. Bladder symptoms, if present, do not vanish yet.

Days 5 to 14

The physical symptoms fade and sleep starts to repair. Cravings become situational: a Friday night, a fight, the drawer where the lozenges were. Thinking is often still foggy.

Weeks 3 and beyond

Mood and thinking keep improving for weeks; the ACMD notes that ketamine's effects on cognition "are at least partially reversible" (ACMD, 2026). The bladder is the slowest healer. In one review, stopping was associated with "substantial (but not necessarily complete) reduction of urological symptoms within 3 months" in about three-quarters of patients, not all (Andrade, 2025). This is also when return to use quietly happens, because the reason people used is still there.

Ketamine bladder, K-cramps, and the liver

Ketamine damages organs that other recreational drugs leave alone. The Spravato label warns that "Cases of ulcerative or interstitial cystitis have been reported in individuals with long-term off-label use or misuse/abuse of ketamine" (section 5.10). The ACMD estimates that "About a quarter of people who use ketamine regularly report at least one urinary symptom," and warns that "These effects may not resolve, or only partially resolve, if ketamine use is discontinued" (ACMD, 2026). The mechanism is the urine itself: "direct exposure of bladder epithelial cells to ketamine or norketamine causes barrier damage, inflammation, and cell death," with uropathy tied to "high-dose (>1 g/d) and long-duration (median, 35 months)" use (Andrade, 2025). Cystitis has now been described in a patient receiving ketamine for depression, so a prescription is not protection (Chang et al., BJPsych Open, 2025).

The ACMD also reports that "Ketamine use may also be associated with chronic abdominal pain, sometimes with vomiting, sometimes referred to as 'K-cramps'," affecting more than a quarter of regular users (ACMD, 2026). And the liver: the Ketalar label warns that "Ketamine administration is associated with hepatobiliary dysfunction (most often a cholestatic pattern), with recurrent use" (section 5.6), and the ACMD puts "Cholestatic liver injury and chronic dilatation of the bile ducts" at "about 10% of those who use the drug regularly" (ACMD, 2026). If you have used heavily, ask a doctor for a urinalysis and a liver panel.

How treatment works

There is no FDA-approved medication for ketamine use disorder and no taper protocol the way there is for benzodiazepines. Treatment is behavioral, and the honest summary of the evidence is the ACMD's: limited and of low quality (ACMD, 2026). In practice, programs borrow what works for other drugs without a medication: cognitive behavioral therapy, motivational work, contingency management where it exists, and treatment for the depression or anxiety ketamine was covering. SAMHSA's National Helpline, 1-800-662-4357, is a free, confidential treatment referral service for individuals and families (SAMHSA). Anyone with urinary symptoms needs a urologist, because "early diagnosis of KIC and immediate cessation of ketamine use has been shown to improve symptoms, reverse early disease and prevent further damage" (Chang et al., 2025).

A word about prescribed ketamine. Spravato is dispensed only under a REMS program that "requires esketamine to be dispensed and administered in medically supervised health care settings," where "Patients must be monitored by a healthcare provider for at least 2 hours" (FDA, 2023; Spravato label). Compounded ketamine mailed to your house has none of that. The FDA warns that "At-home administration of compounded ketamine presents additional risks because a health care provider is not available onsite to monitor for serious adverse outcomes" (FDA, 2023). If you are in a home ketamine program and it has started to feel like a habit, say so to the prescriber and to us.

Ketamine with alcohol, benzodiazepines, or opioids

On its own, ketamine rarely stops breathing at recreational doses. Mixed with depressants, it can. The Ketalar label warns that "Concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death" (section 7.3).

The overdose numbers are small but moving. The CDC found that from July 2019 through June 2023, "Ketamine was detected in 912 (0.4%) overdose deaths," was "listed as involved in 440 (0.2%) deaths, and was the only substance involved in 24 (0.01%) deaths," with the share of deaths where it was detected rising "from 0.3% (47 deaths) to 0.5% (107 deaths)" between the first and last half-year windows of the study (CDC MMWR, 2024). In those deaths, "82.4% of deaths involved either illegally manufactured fentanyls, methamphetamine, or cocaine." The powder in the bag is frequently not alone. Keep naloxone in the house.

Then there is the accident risk. A person deep in dissociation cannot judge heat, height, water, or traffic. The Spravato label tells patients, "Do not drive or operate machinery until the next day after a restful sleep" (section 5.9), and that is for a supervised clinical dose. The ACMD notes that "Those impaired by ketamine may also be at risk of falls, jumping from heights or involvement in fights" (ACMD, 2026). Bathtubs and pools are the hazard families do not think about until it happens.

Drug testing for ketamine

Ketamine is not on standard workplace panels, and it is not on the instant 10-panel saliva strip we use. That strip covers amphetamines, methamphetamine, MDMA, barbiturates, benzodiazepines, buprenorphine, cocaine, methadone, opiates, and oxycodone; a negative result says nothing about K. For that reason, a member whose substance is ketamine has their screening run as the lab-confirmed oral fluid test, analyzed at a CLIA-certified lab with LC-MS/MS confirmation, which reports ketamine and its metabolite norketamine separately, each at a 2 ng/mL cutoff.

How long it stays detectable in saliva is not well established, and we would rather say so than quote a marketing page. Ketamine is short-acting, with an initial half-life of "10 to 15 minutes" and redistribution measured in hours (Ketalar, section 12.3), and its metabolite norketamine lingers longer than the parent drug. In practice the oral fluid window is short, on the order of a day or two after a single dose and longer after heavy daily use. A Spravato treatment will produce a positive; what matters is whether the result matches the plan.

Our members use saliva-based screening that is assigned at random through the week. You do not choose whether you test; you choose who sees the results. For most members that means a coach and, if they want, a spouse, a parent, or the prescriber managing their depression care. We explain the details in our guide to how sobriety monitoring works.

How recovery from ketamine works with Accountable

We are not a detox and we do not prescribe. The urology referral and the depression treatment belong to your doctors. What we provide is the structure around them, at home, for as long as you need it.

1. Get the full picture

In the first sessions your coach maps what is actually going on: how much and how often, whether it started as a prescription, whether you have bathroom symptoms or cramps you have not told a doctor about, and what else is in the picture, including alcohol and benzodiazepines. If you have never had a urinalysis or liver panel, we push for one early. With your permission we coordinate with your prescriber or therapist so nobody is working from half the story.

2. Build a plan that fits your life

Ketamine use tends to be woven into specific hours: the Friday come-down, the 11 p.m. lozenge, the Sunday night before work. Your coach helps you plan for those hours, including who you text before you open the drawer. Daily peer group meetings give you people at those hours, and the weekly family Zoom group gives your partner or parents a place to bring their own fear.

3. Weekly check-ins through the long stretch

The hard stretch with ketamine is weeks three through twelve, when the body feels fine and the mind is still foggy. Your coach shows up every week through that. The lab-confirmed saliva screening turns "I think she's stopped" into a shared record you control. When a slip happens, we treat it as information: the plan changes and the support goes up. Every coach at Accountable has their own recovery behind them.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

Is ketamine addictive?

Yes. The FDA label states that "Physical dependence has been reported with prolonged use of ketamine" and that "Tolerance has been reported with prolonged use of ketamine" (Ketalar, section 9.3). The pull is mostly craving rather than physical sickness, which is exactly why people underestimate it.

How long does ketamine withdrawal last?

The physical part is short. The labels list craving, fatigue, poor appetite, and anxiety after stopping heavy daily use (Spravato, section 9.3), and the ACMD says symptoms "may last several days" (ACMD, 2026). Cravings and low mood can run for weeks; bladder symptoms can take three months or more.

How long does ketamine stay in your system?

Not long. The initial half-life is 10 to 15 minutes and the drug redistributes over a few hours (Ketalar, section 12.3); its metabolite norketamine is detectable somewhat longer. In saliva the window is on the order of a day or two after a single dose and longer with daily use.

Can ketamine really damage your bladder?

Yes. The Spravato label warns of "ulcerative or interstitial cystitis" with long-term use or misuse (section 5.10), and about a quarter of regular users report urinary symptoms (ACMD, 2026). Frequency, urgency, pain, or blood in the urine means see a doctor now; early damage often improves once use stops, late damage may not.

What should I do if someone on ketamine will not wake up?

Call 911, put them on their side, and stay with them. If there is any chance opioids or a contaminated supply are involved, give naloxone; most ketamine-involved overdose deaths also involve fentanyl, methamphetamine, or cocaine (CDC MMWR, 2024). Ketamine mixed with alcohol or benzodiazepines can slow breathing to a dangerous level (Ketalar, section 7.3), so treat it as an emergency, not a nap.

Sources

• Drug Enforcement Administration, Diversion Control Division. Ketamine, drug and chemical information sheet, March 2025.

• Drug Enforcement Administration. Ketamine drug fact sheet.

• U.S. Food and Drug Administration. Ketalar (ketamine hydrochloride) injection, prescribing information, revised August 2020.

• U.S. Food and Drug Administration. Spravato (esketamine) nasal spray, prescribing information, revised April 2025.

• U.S. Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. Compounding risk alert, October 10, 2023.

• Advisory Council on the Misuse of Drugs (UK). Ketamine: an updated review of use and harms. January 28, 2026.

• Vivolo-Kantor AM, Mattson CL, Zlotorzynska M. Notes from the Field: Ketamine Detection and Involvement in Drug Overdose Deaths, United States, July 2019 to June 2023. MMWR Morbidity and Mortality Weekly Report. 2024;73:1010-1012.

• Andrade C. Ketamine-Associated Uropathy During Therapeutic and Nontherapeutic Use: Prevalence, Clinical Features, Mechanisms, and Strategies for Risk Reduction. Journal of Clinical Psychiatry. 2025;86(4):25f16083.

• Chang M, Young A, Juruena M. Ketamine Cystitis Following Ketamine Therapy for Treatment Resistant Depression: Case Report. BJPsych Open. 2025;11(S1):S295.

• Substance Abuse and Mental Health Services Administration. SAMHSA's National Helpline, 1-800-662-HELP (4357).